Organon & Co. (OGN) shares surged 16.87% on Monday to close at $13.16, sealing a two-day rally that added roughly 50% to the stock after the company confirmed it had agreed to be acquired by Sun Pharmaceutical Industries, India’s largest drugmaker.
The all-cash deal values Organon at $14 per share, a premium of more than 24%. Trading volume exploded to 133.6 million shares, roughly 16 times the three-month average.
The announcement landed just one trading day after Organon soared about 31% on Friday, when India’s Economic Times reported that Sun Pharma, Germany’s Grünenthal and Swedish private-equity firm EQT were each circling the women’s health specialist. Monday’s news confirmed Sun Pharma had clinched a definitive agreement.
For Organon, the buyout offers an exit from a punishing four-year run as an independent public company. Since its 2021 spin-off from Merck, the stock had shed 60% of its value, dragged down by a debt pile that far outweighed its equity base. As of Dec. 31, 2025, the company carried $8.6 billion in debt against just $574 million in cash, with annual interest payments of about $500 million eating into profitability. Revenue for the year reached $6.2 billion, generating $1.9 billion in adjusted EBITDA, yet even after Monday’s surge the market capitalization sat near $3 billion.
“After evaluating a range of strategic alternatives, the board concluded that this all-cash offer delivers substantial and immediate value for our stockholders,” Executive Chair Carrie Cox said in a statement.
The transaction hands Sun Pharma a portfolio of more than 70 products spanning women’s health, general medicines and biosimilars, marketed across roughly 140 countries. Executive Chairman Dilip Shanghvi said Organon’s global footprint and capabilities are highly complementary to his own company. “This represents a significant opportunity to advance our vision,” he said.
Combined, the two companies would generate annual revenue of $12.4 billion, elevating the merged entity into the ranks of the world’s top 25 pharmaceutical companies by sales. It would become the seventh−largest biosimilar player globally and a top−three company in women’s health.
Both boards have signed off on the deal, which is expected to close in early 2027, subject to regulatory approvals and a vote by Organon shareholders. Sun Pharma plans to fund the purchase using cash on hand and committed bank financing. Its own shares rose about 7% in Mumbai trading following the announcement.
At Monday’s close of $13.16, Organon shares left a spread of roughly 6% against $14 takeover price — a gap that largely accounts for the time to an early-2027 completion and lingering regulatory uncertainties.
